Actively Recruiting
Randomized Trial Comparing Multimodality Therapy with Standard Systemic Treatment in HER2-Positive Stage IV Oligometastatic Breast Cancer
Led by SWOG Cancer Research Network · Updated on 2026-10-13
562
Participants Needed
59
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the impact of adding locoregional treatments such as surgery and radiation, along with metastasis-targeted stereotactic body radiation therapy SBRT, to the usual HER2-targeted systemic therapy for patients with HER2-positive stage IV breast cancer that has spread to other parts of the body or to a limited number of sites oligometastatic. The study compares this multimodal approach to standard systemic therapy alone, aiming to assess overall survival and disease progression outcomes. This phase III trial includes patients whose cancers respond partially or completely to initial systemic therapy and also observes those with stable or progressing disease. Participants first receive standard HER2-targeted systemic treatments for 12 to 24 weeks, possibly including immunotherapy and chemotherapy drugs. Those with a positive response are randomized into two groups one group undergoes surgery and locoregional radiation therapy, followed by SBRT targeting metastatic lesions, then resumes systemic therapy the other group continues systemic therapy alone. Patients without a response continue systemic therapy in an observational cohort. Procedures such as breast conserving therapy or total mastectomy, radiation therapy with or without boost doses, and SBRT are delivered within specific timeframes post initial treatment. Throughout the study, participants undergo various imaging tests including echocardiography ECHO, MRI, mammography, ultrasound, CT, and PETCT scans, with optional biopsies and blood sample collections. Researchers monitor overall survival and progression-free survival for up to 10 years after treatment, with follow-up visits at regular intervals. The study also tracks treatment adherence, disease status, and side effects, aiming to understand the long-term effects of adding locoregional therapies to systemic treatment in this patient group.
CONDITIONS
Brief Title
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here